5 Health Risks You Face Due to Lack of Sleep – News18

Lack of sleep does more harm than leaving you with dark circles. While short-term effects can be brain fog, lack of concentration, and fatigue, the long term effects are much worse. All individuals should get a sound sleep of at least 8 hours though it may vary depending on your age and occupation. However, many factors like stress, health issues like sleep apnea can cause a hindrance in this. The long-term effects range from physical as well as mental health issues.

Here are five health risks you might have to deal with if you suffer from lack of sleep or insomnia.

Dementia

According to WebMD, there is a U-shaped curve when it comes to sleep length and cognitive decline. If you sleep too much or too little, several health issues may arise. Lack of sleep is more likely to increase the risk of dementia. If you are having trouble sleeping, especially if you are in your 50s and 60s, consult a healthcare practitioner. While this does not necessarily mean you have Dementia, your healthcare practitioner can help you figure out what is causing you sleep troubles.

Depression

A recent study by researchers at the Johns Hopkins University, United State, has found a connection between depression and sleep problems. People with insomnia have ten times more chances of developing depression than those who get a good nights sleep, according to the researchers. Patrick H Finan, an expert in behavioural medicine and sleep researcher at Johns Hopkins Hospital says, Poor sleep may create difficulties regulating emotions that, in turn, may leave you more vulnerable to depression in the futuremonths or even years from now. And depression itself is associated with sleep difficulties such as shortening the amount of restorative slow-wave sleep a person gets each night.

Effect on Endocrine System

Sleep deprivation can impact the production of hormones. That means endocrine disorders, in particular metabolic disorders, can impact your body. An interruption in growth hormone production can adversely impact the growth of muscle mass and repair cells as well as tissues, along with other functions. Full functioning of the pituitary gland, too, requires adequate sleep.

Cardiovascular Diseases

Lack of sleep also increases the risk of developing cardiovascular diseases. Your bodys ability to heal and repair blood vessels is put at jeopardy when you dont get enough sleep. These interrelated health issues can be kept at bay by following a sleeping cycle, doing enough physical exercise during the day, and avoiding eating a few hours before bed time.

Respiratory Problems

Waking up throughout the night can leave you more vulnerable to respiratory infections like, common cold and flu. Existing respiratory diseases like chronic lung illness can also become worse due to inadequate sleep. This is because your immune system is being prevented from building its defences. The immune system produces infection-fighting elements like antibodies and cytokines that fend off viruses and bacteria.

Read all the Latest Lifestyle News and Breaking News here

The rest is here:

5 Health Risks You Face Due to Lack of Sleep - News18

Does intermittent fasting work? The Varsity – Varsity

Content warning: This article discusses weight loss strategies.

The quickest way to lose weight is subjective to how you view different fitness techniques and regimens. Intermittent fasting is the selective timing of various meals that cycle your body to accommodate voluntary fasting and non-fasting over a period of time. Periodic fasting, alternate-day fasting, and daily time-restricted feeding are some of the multiple types of ways you can induce weight loss techniques in your daily life. However, is intermittent fasting really that effective?

Skipping meals may not be the best way to manage your weight; however, it does come with benefits. A typical day in the life of this technique would have you eat for roughly eight hours and fast for the remaining sixteen. Essentially, this would limit your intake of foods, as well as calorie-containing beverages, because you would only be consuming no-calorie beverages such as coffee or tea. Over time, your metabolism will start to increase and help you burn calories even faster.

Many scholarly experiments have concluded that intermittent fasting does work, although it may not be the best for your overall short-term health. Taking a deeper look into what happens on a cellular level, its fascinating to see how much food influences your body.

When we dont consume food for a while, many different things happen in our body simultaneously. Insulin levels drop, human growth hormone (HGH) levels increase, the body moves into a cellular repair process, and the genes in our DNA beneficially increase their longevity and protection against diseases. Backtracking for a quick second, our insulin levels are the main source behind helping our fat burn the way it does. That is why, during the fasting stage of this weight loss technique, there is no food in our body to facilitate the burning of any excess fat.

Our blood levels also increase dramatically, as were now running on the food we ate during the eight-hour period. Thats why, when we complete activities like walking up the stairs, some of us may start to feel our heartbeat quickening and maybe even start to fall short of breath.

These changes in hormone and gene function ultimately train our bodies to facilitate weight loss. Lower insulin levels and higher HGH levels increase the breakdown of body fat and channel it into energy. When intermittent fasting, our bodies increase their metabolic rate, therefore increasing the calories that are expended. In addition to this, we consume less food, which decreases our calorie intake.

From a long-term standpoint, intermittent fasting also helps to lower your risk of type two diabetes, oxidative stress, and body inflammation. However, if there are all these benefits to this weight loss regimen, why is it not as popular and frequently used as others? In todays world, its a formality to know that with all good things, there are some drawbacks.

Intermittent fasting contributes to frequent headaches. This makes it so that when we do put food into our bodies, our digestive system suffers some issues such as uneasiness and constipation. Its also not surprising to know that food contributes to our overall moods, as well. Speaking from personal experience, people can start to get quite irritable when hungry.

Mood disturbances and a lack of concentration were of the most commonly reported conditions experienced by women in a 2016 study on the effects of short-term fasting on healthy women. Intermittent fasting isnt a one-size-fits all model, and for some, the negatives may outweigh the positives.

Promoting a good overall lifestyle can be done by consuming food in moderation compared to a short-term rigorous regimen. Overall, intermittent fasting is a functional approach to weight loss and you can most definitely go about your weight loss goal in a variety of different ways that suit your nutritional needs and target goals.

Read the original here:

Does intermittent fasting work? The Varsity - Varsity

Super-fit Dana White hits back at douche over steroid accusations – BJPENN.COM

Dana White has never been fitter in his life, and he owes the change to human biologist and mortality expert Gary Brecka, who initially diagnosed him with just 10 years to live. Not, as some online have suggested, to steroids.

According to White, Brecka took a full blood panel and quickly identified several worrisome health markers, including a triglyceride count above 750mg/dL. For reference, the normal range sits below 150, meaning the UFC president was one more UFC 279 incident away from a stroke.

Following Breckas custom tailored program, White has shed a ton of weight, revealing a solid set of six-pack abs which he showed off on Instagram. Of course it didnt take long for someone to accuse him of being on the sauce, posting Steroids in the comments.

White fired back, writing The douche who said steroids is the type of person u cant help. 10X health system is incredible and has changed my life.

While its unclear exactly what protocol Brecka had White on to turn his health around, his 10X Health Systems website offers a variety of tools like oxygen generators, electro-magnetic field therapy mats, and infrared light beds. On LinkedIn, Brecka also offers custom designed hormone therapy services to treat hormone imbalance or low testosterone issues.

Regardless of whether White is indeed on performance enhancing drugs, it doesnt take away from the fact that he was extremely unhealthy and looking at an early grave. Now hes looking healthier than ever, and feeling amazing as well.

I did everything he said, to the letter, White told the Action Junkeez podcast. I lost 30 pounds. My legs were so f***ed up 13 weeks ago, I couldnt tie my shoes. Couldnt bend over to tie my shoes, because my legs were f***ed up. I could barely walk some days. No more sleep apnea, I dont snore anymore. Everything is gone in ten f***ing weeks. Ive been working with doctors for 10 years that couldnt do it.

So whether Whites health improvements are a result of steroids or hGH or stem cells or peptides, you cant argue with the end results. And so long as hes not competing in the Olympics (or the UFC), does it matter whether his treatment would be banned by USADA?

Let us know what you think of Dana Whites transformation in the comments, PENN Nation!

Continued here:

Super-fit Dana White hits back at douche over steroid accusations - BJPENN.COM

Human Growth Hormone Treatment & Drugs Market Will Generate Booming Growth Opportunities to 2032 – PharmiWeb.com

The globalhuman growth hormone treatment & drugs market shareis projected to grow at a moderateCAGR of 3.3%, reaching nearlyUS$ 4.8 Bnby 2032 fromUS$ 3.4 Bnin 2021.

Industry participants investments, the presence of a solid pipeline, extensive R&D efforts, a comprehensive product portfolio, and expanding government initiatives are all projected to drive the demand for human growth hormone treatment & drugs.

The global human growth hormone treatment & drugs market share is expected to be impacted by the COVID-19 epidemic. Patients with low growth hormone secretion are at risk for COVID-19, which necessitates immediate intervention to aid in COVID-19 prevention.

Patients with Prader-Willi syndrome, on the other hand, must exercise caution in order to reduce their risk of contracting COVID-19. Furthermore, people with Prader-Willi syndrome may not exhibit typical symptoms such as a high fever or a higher-than-normal pain threshold, delaying the diagnosis of COVID-19.

Turner syndrome patients are at an increased risk of contracting the COVID-19 virus, which can cause serious disease.

Download Sample Copy @https://www.futuremarketinsights.com/reports/sample/rep-gb-14401

Human growth hormone manufacturers are investing in research and development to create a growth hormone with fewer side effects and the potential to be a long-term treatment.

The human growth hormone supplements market is growing due to an increase in disorders connected to growth hormone insufficiency, an increase in the use of ageing hormones, government and private sector efforts to raise awareness of growth hormone deficit, and high productivity.

Other reasons such as greater understanding of the treatment process, an increase in the number of health conditions, and an increase in the number of neuropsychiatric cases are expected to boost the human growth hormone treatment & drugs market sizes growth. Human growth hormone supplements market expansion is projected to be driven by the quick growth of new human growth hormone novels.

As per the global human growth hormone treatment & drugs market study, the industry is likely to be driven by initiatives taken by various government and private organizations to raise awareness about GH deficiency and human growth hormone treatment.

International Childrens Growth Awareness Day is observed every year by the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a nonprofit charitable organization based in the United States, to increase public knowledge regarding the early detection and intervention of human growth hormone problems, particularly in children.

However, the high price of hGH therapies, as well as severe hGH-related side effects, may negatively impact the human growth hormone for sale over the projection period.

Knee, hip, or other joint discomforts; allergic reactions, such as redness, swelling, or hives; and an increase in blood sugar levels are all possible adverse effects of GH hormone therapy, according to UPMC Childrens Hospital of Pittsburgh.

Request for Report Ask A Question @https://www.futuremarketinsights.com/ask-question/rep-gb-14401

Key Takeaways

A healthy product portfolio and extensive Market research investments for the emergence of future growth hormone treatments are projected to propel the sales of human growth hormone treatment & drugs.

Competitive Landscape

The demand for human growth hormone treatment & drugs is moderately concentrated, with a few key manufacturers owning a large portion of the industry. Furthermore, several active collaborations are underway to generate more effective and long-acting subtypes of human growth hormones.

Key human growth hormone manufacturers include Eli Lilly and Company, Ipsen S.A., EMD Serono Inc., Novo Nordisk A/S, Genentech, Inc (Roche), AnkeBio Co. Ltd, GeneScience Pharmaceuticals Co. Ltd, LG Life Sciences and Ferring Pharmaceuticals.

Pfizer Inc. began a Phase III research trial in February 2021 to assess the efficacy and security of somatropin in a group of Japanese patients with Prader-Willi Syndrome (PWS).

In October 2020, Erasmus Medical Center, in collaboration with Pfizer, the Foundation for Prader-Willi Research, and the Prader-Willi Fonds, launched a Phase III clinical trial to evaluate the impact of growth hormone treatment (Genotropin) on physical and psychosocial wellbeing in adults with Prader-Willi syndrome who are 30 years or older.

Top Related Reports Healthcare Market Insights

https://www.spoke.com/topics/veterinary-electrosurgery-market-revenue-worth-size-segment-by-type-application-key-companies-fmi-633ade90f812856ddc003db5

https://www.pressreader.com/article/6755648566025533

https://www.letsdiskuss.com/post/veterinary-electrosurgery-market-key-players-swot-analysis-key-indicators-and-forecast-by-2032

https://www.scoop.it/topic/automotive-by-vishal-58/p/4136341247/2022/10/03/veterinary-electrosurgery-market-research-segmentation-key-players-analysis-forecast-by-2032?&kind=crawled&fId=1081630

https://odlook.com/post/6116_the-global-veterinary-electrosurgery-market-size-is-estimated-at-us-471-96-milli.html

About Future Market Insights (FMI)

Future Market Insights(ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware 19713, USAT: +1-845-579-5705For Sales Enquiries:sales@futuremarketinsights.comBrowse All Reports:https://www.futuremarketinsights.com/reportsLinkedIn|Twitter|Blogs

More here:

Human Growth Hormone Treatment & Drugs Market Will Generate Booming Growth Opportunities to 2032 - PharmiWeb.com

NFL: After the talk about concussions, how did this happen? | Opinion – Deseret News

No one should be surprised that the NFL failed to back up all the tough talk about player safety and concussions in the Tua Tagovailoa disaster. The league gives a lot of lip service to various causes, but doesnt deliver.

All the much-discussed protocols that were in place to prevent exactly what happened to Tagovailoa the tents on the sideline, the mandatory rest periods for concussions, the official game-day checklist for concussions, etc. fell apart. Tagovailoa not only played punch-drunk through one game but four days later played another game before leaving the field on a stretcher with his brains scrambled.

After all the years of intense discussion and attention given to concussions in football deaths and brain damage and CTE and suicides attributed to repeated blows to the head how did this happen?

The NFL is all talk. The league also keeps telling us how serious it is about sexual abuse. But Deshaun Watson, a serial sex abuser, received a mere 11-game suspension while Calvin Ridley was slapped with a suspension that will last at least one year for gambling on games.

The league gave a lot of lip service to womens health, too. Beginning in 2009, the league made a big production out of its ubiquitous breast cancer awareness campaign each October, with players, cheerleaders, coaches and fans decked out in pink. Proceeds from the sale of that pink merchandise was supposed to go to the American Cancer Society, but what it mostly did was sell more official NFL gear.

As Sports Illustrated put it in a headline, NFLs breast cancer awareness month (is) more about style than substance. After everyone took cuts of the merchandise sales the NFL, merchandise manufacturers, vendors 8.01% of the proceeds went to the ACS, according to ESPN. The league ended the practice in 2016.

The league also gives a lot of lip service to PEDs performance-enhancing drugs (anabolic steroids, human growth hormone, etc.), and, if you read on, youll see this relates to the topic du jour player safety/concussions. Earlier this year USA Today reported that NFL players have been suspended for PED use at least 258 times since 2001, a period of 21 years. That sounds like a lot; its not.

Last year The Guardian reported that in just four years (2017-21) track and field handed out 196 suspensions, including sanctions against 66 Olympic and World Championships medalists. There is an alphabetic list of track and field athletes on the internet who have been suspended for doping violations; the numbers surpassed the NFLs 21-year mark of 258 before the end of the Fs. Cycling is the same story.

It should also be noted that when athletes in track and cycling flunk drug tests, they face real consequences, drawing suspensions that usually are for two years. Shelby Houlihan, the American record holder in the 1,500- and 5,000-meter runs, has been suspended for four years for testing positive for an anabolic steroid.

NFL suspensions are often four to six games and then the players are allowed to play again.

No other athlete benefits more from increased size and strength the benefits of HGH and anabolic steroids than football players, and yet the number of football players who test positive lags well behind track and cycling. Somehow many other PED users seem to evade the tests; it would be naive to think otherwise.

According to ESPN, four decades ago there was one player in the NFL who weighed more than 300 pounds; by 2010 there were more than 500 of them. The size increase far outstrips the increase in size in the general population.

NFL players are not only freakishly big, theyre freakishly fast. Put them on the hard turf fields, and theyre even faster. Its Newtons second law of motion force=mass x acceleration. Translation: bigger (more dangerous) collisions.

On Sept. 25, Tagovailoas head slammed into the turf after being tackled in the second quarter during a game against the Bills. He staggered to his feet, shook his head, jogged a few steps and collapsed to his knees. He passed NFL concussion protocols and was cleared by a doctor to return to the game. Later head coach Mike McDaniel would say Tagovailoas legs got wobbly because his back was loose but that sounded ridiculous. Did anybody really believe that or think Tagovailoa should return to the field? He finished the game, then played against the Bengals just four days later.

Before the Bengals game, former college football player Chris Nowinski, now a neuroscientist and CTE expert, called the back injury explanation nonsense and tweeted, If Tua takes the field tonight, its a massive step back for #concussion care in the NFL. If he has a 2nd concussion that destroys his season or career, everyone involved will be sued & should lose their jobs, coaches included. We all saw it, even they must know this isnt right.

While scrambling against the Bengals, Tagovailoa was thrown to the turf by a 348-pound lineman and didnt get up. He rolled onto his back and brought his hands in front of his face, the fingers stretched and contorted in an odd way. Neurologists call this decorticate posturing, the bodys response to brain damage. He was taken off the field on a stretcher to a local hospital and later released in time to return home with the team, but the public outcry had already begun.

After the game, Nowinski tweeted, This is a disaster. Pray for Tua. Fire the medical staffs and coaches. I predicted this and I hate that I am right. Two concussions in 5 days can kill someone. This can end careers. How are we so stupid in 2022?

It is widely believed that if the brain isnt given time to recover from a first concussion, a second concussion is more likely and will be more severe, potentially causing devastating, long-term effects.

Ive never seen anything like it before, said Ravens coach John Harbaugh. I just couldnt believe what I was seeing.

The response has been swift. Nowinski says Tagovailoa should sit out the rest of the season and never play for the Dolphins again. The NFL Players Association is investigating and has threatened legal action. The NFLPA fired the consultant who cleared Tagovailoa to play. The NFL and the NFLPA have agreed to update concussion protocols that will sideline players who exhibit gross motor instability.

Because Tagovailoas stumble and obvious instability (in the first game) was attributed to his back, and not due to a blow to the head, he did not fall under the concussion protocols and therefore could return to the field. Under the new beefed-up protocols, it wont be up to doctors to decide WHY a player was unstable. If hes unstable, hes out.

Maybe the current concussion protocols were lacking in some way thats highly debatable but you have to wonder: Where was the common sense?

Miami Dolphins quarterback Tua Tagovailoa during game against the Cincinnati Bengals on Thursday, September 29, 2022, in Cincinnati. Tagovailoa was later injured in the game and was taken off the field on a stretcher.

Matt Patterson, Associated Press

The rest is here:

NFL: After the talk about concussions, how did this happen? | Opinion - Deseret News

Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) – Digital Journal

The Acromegaly Market is expected to show positive growth in the forecast period (20222032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

Acromegaly Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. This Acromegaly Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Acromegaly Market report analysis.

Key takeaways from Acromegaly Market Research Report

Know which therapies are expected to grab major Acromegaly Market Share @ Acromegaly Market Research Report

Acromegaly Overview

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.

Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients are not able to put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth.

Surgery is the treatment of choice for all microadenomas as well as macroadenomas, causing a mass effect. Debulking of macroadenomas without mass effect can also be done and has been described as a modality to allow for better response to medical treatment even if a surgical cure is not likely. The best predictors of surgical cure include smaller tumor size, lower levels of GH/IGF-1, and absence of invasion of surrounding structures such as the cavernous sinus. All of these drugs are synthetic somatostatin and bind to somatostatin receptors.

Acromegaly Epidemiology Insights

Acromegaly is a very rare disorder caused, in most cases, by a tumor of the pituitary gland that produces too much growth hormone (GH). Nearly all pituitary tumors, including those that cause acromegaly, are benign, and not malignant. However, they can become quite large and expand beyond the normal confines of the pituitary gland.

Acromegaly Epidemiology Segmentation in the 7MM

For further information of this report to understand which factors are driving Acromegaly Epidemiology trends @ Acromegaly Epidemiological Insights

Acromegaly Treatment Market

The current treatment method for Acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas, and on reducing GH and IGF-1 levels to normal. Although, the primary treatment method for Acromegaly is transsphenoidal surgery, although all the patients are not eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery. The cure rate of surgery is about 80% for microadenomas and 4050% for macroadenomas.

Acromegaly Pipeline Companies

Acromegaly Market Insights

As per the literature reviews by Lim et al., titled The role of combination medical therapy in the treatment of acromegaly, pegvisomant and SSA combination has demonstrated good biochemical control in the majority of patients, and may allow individual drug dosage reductions, but patients require close monitoring for liver enzyme elevations. The combination of cabergoline, to SSA is relatively well tolerated and most likely to be effective in patients with very mild IGF-1 elevations. It was also found that the combination of pegvisomant and cabergoline may be useful in a select group of patients with mild IGF-1 elevations, particularly in the setting of intolerance to SSA or when the cost of SSA-Peg therapy is prohibitive.

Learn more about the Acromegaly Therapies in clinical trials @ Drugs for Acromegaly Treatment

Acromegaly Emerging Therapies

The emerging therapies for the treatment of Acromegaly includes Octreotide capsules (Chiasma Pharma), Veldoreotide (Strongbridge Biopharma), CAM2029 (Camurus), CRN00808 (Crinetics Pharmaceuticals), IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), and MTD201 (Midatech). Octreotide capsules have been granted orphan designation in the US and the European Union for the potential treatment of Acromegaly.

Scope of the Acromegaly Market Research Report

Discover more about Acromegaly Medications in development @ Acromegaly Clinical Trials

Table of Content

1. Key Insights

2. Acromegaly Executive Summary

3. Competitive Intelligence Analysis

4. Acromegaly: Market Overview at a Glance

5. Acromegaly: Disease Background and Overview

6. Patient Journey

7. Acromegaly Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Acromegaly Unmet Needs

10. Key Endpoints of Acromegaly Treatment

11. Acromegaly Marketed Products

12. Acromegaly Emerging Therapies

13. Acromegaly: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Acromegaly Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Acromegaly Market Drivers

19. Acromegaly Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Get in touch with our Business Executive @ Acromegaly Market Trend

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/

Read this article:

Acromegaly Market Size was USD 1326.6 million in 2021 and it is expected to rise during the study period (2019-2032) - Digital Journal

Aaron Judge Ties the Real Home Run Record – Rolling Stone

No, those steroid-fueled home run hitters don't count

Aaron Judge just made history during the Yankees game against the Toronto Blue Jays. Officially, he tied the all-time American League (and New York Yankees) record for most home runs in a season, held by Roger Maris since 1961. But for baseball purists (like my editor who forced me to write that headline), Judge tied the record for all-time home runs in a season league-wide.

During the 7th inning against the Toronto Blue Jays, the California native hit the ball over the bullpen and against the left field wall, marking his 61st home run this season. The two-run homer broke a three-three tie and cemented Judges place in the history books. Earlier this month, he tied Babe Ruths nearly century-old 60-home run mark, becoming the third Yankee to hit 60 homers.

The official record-holder is San Francisco Giants legend Barry Bonds, who broke the record in 2001, hitting 73 homers in a single season. The catch? Homie was juiced on steroids and other banned substances. According to Forbes, Bonds used injectable anabolic steroids, injectable human growth hormone, post cycle therapy drugs, and amphetamines, between 2001 and 2006, when he reached the No. 1 ranking for all-time home runs at 762.

Judge who has played for the Yankees since 2016 has been selected as an MLB All-Star four times: in 2017, 2018, 2021, and 2022. He was also the American League home run leader and Rookie of the Year in 2017.

Read more here:

Aaron Judge Ties the Real Home Run Record - Rolling Stone

The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast…

ReportLinker

Protein therapeutic medicines are a class of pharmaceuticals used to treat a range of illnesses, including cancer, metabolic, hematological, immunological, hormonal, genetic, contagious diseases, and others.

New York, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Protein Therapeutics Market Size, Share & Industry Trends Analysis Report By Product, By Application, By Regional Outlook and Forecast, 2022 2028" - https://www.reportlinker.com/p06322275/?utm_source=GNW These medications could greatly enhance human health. Protein distribution in appropriate amounts to the body to enable the precise functioning of various glands, as well as other organs in the body, is the basic concept behind protein therapy, which is conceptually related to gene therapy.

Genetically modified versions of naturally produced human proteins are called therapeutic proteins. They can be utilized to swap out proteins that are defective or lacking in a particular condition. They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness. The proteins produced by genetic engineering can be made to closely match the natural proteins they are meant to replace, or they can be improved by the addition of sugars and other compounds that prolong the proteins activity.

A protein that is defective or lacking in a certain condition can be replaced with therapeutic proteins. They can also increase the bodys production of a helpful protein to lessen the effects of illness or chemotherapy. The proteins produced by genetic engineering may closely resemble the natural proteins they are intended to replace, or they may be improved.

Covid-19 Impact Analysis

The COVID-19 pandemic severely hampered the economy all over the world. A number of businesses were significantly demolished by the abrupt emergence of the pandemic. Moreover, several manufacturing and production facilities were closed owing to the outbreak due to the lockdown imposed by various governments within their countries. The protein therapeutics market was also disrupted in the initial period of the pandemic. Lockdown caused major delays within the development and delivery of crucial medical supplies. Attributed to this, the production of therapeutic protein was impeded.

Market Growth Factors

An increase in the cases of cancer across the world

One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world. Any disease that can affect any region of the body is referred to as cancer. Neoplasms and malignant tumors are other words that are used to denote this disease. One characteristic of cancer is the quick development of aberrant cells that expand outside of their normal borders, infiltrate other body components, and eventually move to other organs. This process is known as metastasis. The main reason why cancer patients die is because of widespread metastases within their bodies.

Rising focus of governments and regulatory bodies in accelerating the process of approval for this practice

A significant number of people in various developed, as well as developing nations who suffer from uncommon and complex diseases, depend on plasma-derived therapies every day as essential, life-saving medications. The need for these treatments, in particular immunoglobulins, has grown significantly and is still growing on a global scale. Plasma-derived therapies are treatments made from human plasma through a fractionation procedure in which the pertinent plasma proteins are isolated. The single largest component of human blood is called plasma, which is made up of proteins, salts, enzymes, and water. Primary and secondary immunodeficiencies, bleeding disorders, inhibitor deficiencies, and other rare diseases are all treated with plasma-derived medicines.

Market Restraining Factors

High manufacturing and administration cost

A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies. Because of high product prices, some therapies that patients need for a speedy and complete recovery are no longer available. In several nations, prices are additionally governed by law. Through their authority over national healthcare organizations, which can cover a significant portion of the cost of distributing drugs to consumers, government bodies restrict costs.

Product Outlook

On the basis of Product, the Protein Therapeutics Market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone. In 2021, the Insulin segment garnered a significant revenue share of the protein therapeutics market. The rise in the growth of the segment is majorly attributed to the increasing cases of diabetes all over the world. Insulin is a natural hormone, which is produced by the pancreas. The lack of production of this hormone is the factor that stimulates the diabetes level of the human body.

Application Outlook

By application, the Protein Therapeutics Market is segregated into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others. In 2021, the metabolic disorders segment procured the biggest revenue share of the protein therapeutics market. The rise in the growth of the segment is due to the exponential demand for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segments growth.

Regional Outlook

Region-wise, the Protein Therapeutics Market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. In 2021, North America held the largest revenue share of the protein therapeutics market. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. Moreover, North American countries are early adopters of several new technologies and approaches.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Protein Therapeutics Market. Companies such as Merck & Co., Inc. Amgen, Inc., Eli Lilly and Company are some of the key innovators in Protein Therapeutics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.

Recent Strategies Deployed in Protein Therapeutics Market

Partnership, Collaboration and Agreements:

Aug-2022: Merck came into a collaboration with Orna Therapeutics, a biotechnology company. Following this collaboration, the companies would work on the discovery, development, and commercialization of multiple programs, encompassing therapeutics and vaccines in the sector of infectious disease and oncology.

Mar-2022: Novo Nordisk joined hands with Massachusetts Institutes of Technology and Brigham and Womens Hospital. Through this collaboration, the company aimed to leverage the distinct prospect to bring new transformational solutions to patients by utilizing its distinct capabilities.

Jan-2022: Amgen teamed up with Amgen Generate Biomedicines, a therapeutics company. Under this collaboration, the companies aimed to develop and manufacture protein therapeutics to address 5 clinical ailments.

Jan-2022: Merck teamed up with Absci, the drug, and target discovery company. Following this collaboration, Merck aimed to leverage Abscis platform to utilize its compelling opportunity intending to develop new biologic candidates as well as explore complex protein expression.

Aug-2021: Eli Lilly and Company joined hands with Lycia Therapeutics, a biotechnology company. Following this collaboration, the companies aimed to focus on the development, manufacturing, and marketing of new targeted therapeutics leveraging the proprietary lysosomal targeting chimera protein degradation technology of Lycia.

Sep-2020: Merck collaborated with Seattle Genetics, an American biotechnology company. With this collaboration, the companies aimed to further expand the oncology portfolio of Merck in order to enhance the lives of cancer patients.

Acquisition and Mergers:

Jun-2022: Pfizer took over ReViral, a privately held, clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to integrate RSV investigational treatments of ReViral into its portfolio in order to acquire an offering of promising therapeutic candidates.

Nov-2021: Pfizer took over Trillium Therapeutics, a clinical-stage immuno-oncology company. This acquisition aimed to offer an impressive portfolio, including biologics, to Pfizer

Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobios antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.

Jul-2021: Eli Lilly and Company completed its acquisition of Protomer, a pre-clinical stage biotechnology company. Under this acquisition, the company aimed to help Protomer in enhancing its diabetes range with its innovative technology.

Feb-2021: Merck took over VelosBio, a privately held clinical-stage biopharmaceutical company. Through this acquisition, the company aimed to boost its expanding oncology portfolio while also strengthening its long-term growth potential.

Aug-2020: Johnson & Johnson completed its acquisition of Momenta Pharmaceuticals, a biotechnology company. This acquisition aimed to strengthen Janssens position in the autoimmune diseases sector and offer a major catalyst for sustained growth of the company.

Approvals and Trials:

Sep-2020: Baxter International received the US FDA approval for its Clinimix and Clinimix E. The new formulations aimed to complement the offerings of medical formulations with their higher protein content.

Scope of the Study

Market Segments covered in the Report:

By Product

Monoclonal Antibodies

Human Growth Hormone

Fusion Protein

Insulin

Erythropoietin

Interferon

Follicle Stimulating Hormone

By Application

Metabolic Disorders

Immunologic Disorders

Hematological Disorders

Cancer

Hormonal Disorders

Genetic Disorders

Others

By Geography

North America

o US

o Canada

o Mexico

o Rest of North America

Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

Abbott Laboratories

Baxter International, Inc.

Amgen, Inc.

F. Hoffmann-La Roche Ltd.

Eli Lilly And Company

Merck & Co., Inc.

Johnson & Johnson (Janssen Global Services, LLC)

Pfizer, Inc.

Novo Nordisk A/S

Sanofi S.A.

Unique Offerings

Read the original:

The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast...

Biosimilars Market to reach a size of US$ 100.5 Bn by the end of 2032 – GlobeNewswire

New York, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Rapid growth of the pharmaceutical realm and higher prices of existing biological drugs are likely to foster attractive growth avenues in the biosimilars market. Biosimilars market is expected to reach US$ 100.5 Bn by the year 2032 as compared to the value of US$ 30.1 Bn at present. The market is slated to witness a CAGR of 14.1% between 2022 and 2032

Biosimilars are known for various economic and clinical benefits, which are poised to take the entire healthcare vertical by storm in the near future. RND Corporation has also certified that increasing frequency of these drugs worldwide is likely of increasing direct spending regarding biologics by close to US$ 54 Bn by the year 2026.

At the same time, easy availability of generic drugs is likely to restrain the biosimilars market in the forecast period.

Request for sample copy of report: https://www.persistencemarketresearch.com/samples/2782

Key Takeaways from Biosimilars Market

Biosimilars cost-effectiveness renders them one of the preferred choices to treat several rare and chronic diseases at the global level. says an analyst belonging to Persistence Market Research

Get customized report as per requirement: https://www.persistencemarketresearch.com/request-customization/2782

Market Competition

Persistence Market Research has mentioned about the key developments in biosimilars market. They include partnerships, agreements, collaborations, and likewise.

Get full access of report: https://www.persistencemarketresearch.com/checkout/2782

What does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the biosimilars market in its latest study, presenting historical demand assessment of 2016 2021 and projections for 2022 2032.

The research study is based on the type of product (recombinant glycosylated proteins and recombinant non-glycosylated proteins), by application (hematology, growth hormone deficiency, oncology, diabetes autoimmune, disease, and likewise), and distribution channel (online pharmacies, hospital pharmacies, and retail pharmacies).

Other Trending Reports:

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies/clients shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Rajendra Singh

Persistence Market Research U.S. Sales Office:305 Broadway, 7th FloorNew York City, NY 10007+1-646-568-7751United StatesUSA - Canada Toll-Free: 800-961-0353Email: sales@persistencemarketresearch.com

Visit Our Website:https://www.persistencemarketresearch.com

Rapid growth of the pharmaceutical realm and higher prices of existing biological drugs are likely to foster attractive growth avenues in the biosimilars market.

See original here:

Biosimilars Market to reach a size of US$ 100.5 Bn by the end of 2032 - GlobeNewswire

Patents to biological medicines in combination: is two really better than one? – Lexology

New medicines are usually protected by a patent covering the active molecule. These basic or primary patents usually provide robust protection for the relevant product, provided that the compound is genuinely new and inventive. Developers may be able to extend patent protection by patenting other technological advances related to the drug such as new formulations, dosage forms or regimens, and new combinations with other pharmaceuticals. These secondary patents can provide a significantly extended period of patent protection for the drug, provided of course that they are valid.

The same principles apply to the patenting of biological drugs (biologics). Biologics include large peptides and recombinant proteins such as insulin and growth hormone, monoclonal antibodies, recombinant DNA, antibody-drug conjugates, fusion proteins and synthetic vaccines. In contrast, small molecule drugs are usually chemically and thermally stable with low molecular weights.

Given the often significantly greater expense involved in the development of biologics (compared to small molecule drugs), and originator companies need to recoup that cost, it is unsurprising that secondary patents often play a key role in the lifecycles of biologics. As the basic patents on blockbuster biologics expire, there will be increasing interest in testing the strength of secondary patents, particularly from companies that produce biosimilars.

Patents for biologic and small molecule combinations

Secondary patents for drug therapy combinations can cover co-formulations (where the active ingredients are combined in a single product), combination products (such as dual-barrel syringes) and co-administration of different products simultaneously. For the purpose of this article, drug combinations are considered in their broadest sense, that of co-administration.

It is now common medical practice to use biologics in combination therapy, usually with a small molecule drug. But are the secondary patents to this kind of drug combination worthy of patent protection?

One reason why patents for biologic and small molecule combinations may not always be robust is because the co-administration of two or more medicines to treat disease is often a routine medical practice. In some fields, notably HIV medicine and oncology, monotherapy is unusual. This practice has transformed the efficacy of treatment of many diseases. As such, drug combinations which include at least one routinely used drug (often a small-molecule compound) are likely to be considered obvious from a patentability perspective, particularly where that drug is used in other combinations.

The approach of the European Patent Office (EPO)

Inventions are only entitled to patent protection if they are new and not obvious to a skilled person working in the relevant technical field. However, the approach of the EPO to the assessment of whether an invention for a combination of drugs is obvious tends to favour patent applicants. This is because the EPO does not, as a matter of routine, consider evidence on this question from relevant experts (although such evidence may be submitted by third parties opposing the grant of a patent). Rather, the EPOs analysis centres on whether the disclosure of earlier prior art documents would make the invention obvious. If an applicant is able to provide data to the EPO which demonstrates that a combination of drugs is particularly efficacious, a patent is often granted. This can be the case even if one of the drugs is already in routine use for the claimed medical indication. This is because, if one of the claimed drugs is relatively new, there are unlikely to be any prior art publications which disclose that the particular combination works.

Whether a combination is considered obvious may also depend on the medical field in which the compounds are used. In some specialities, routinely-used combinations tend to contain the same backbone drug, with variation only in the remainder of the combination.

As an example, combination therapies for rheumatoid arthritis commonly contain the antifolate drug methotrexate (MTX). Although biologics may only be prescribed when conventional disease-modifying antirheumatic drugs (DMARDs) have not worked, they are often administered in combination with MTX. Some, such as adalimumab and certolizumab pegol, are primarily licensed for combination use and only used alone in cases of intolerance to MTX.

In cancer care, combination chemotherapy is the gold-standard for many malignancies. This includes regimens using biologicals such as obinutuzumab (Gazyvaro) which is only licensed in the UK for combination chemotherapy, although it may be given on its own for subsequent maintenance therapy.

Similarly, pembrolizumab (Keytruda) is licensed for use with a number of longstanding chemotherapy drugs and, for some indications, with newer classes of chemotherapeutic agents such as the multi-receptor tyrosine kinase inhibitors (for example, lenvatinib).

Obvious drug combinations: examples

Some major biologics have had secondary patents to combinations with small molecule drugs revoked in opposition proceedings before the EPO. One example is rituximab, a chimeric mouse/human monoclonal antibody for the CD20 protein found on the surface of B-lymphocytes that is marketed by Roche in Europe as MabThera and by Genentech in the US as Rituxan.

Rituximab was the first therapeutic antibody approved for oncology patients. It was first authorised in the US in November 1997 and in the EU in 1998 for a particular form of non-Hodgkins lymphoma (a type of blood cancer). Further approvals followed for other medical indications unrelated to cancer, as well as different treatment regimens and drug combinations.

Rituximab is now licensed to treat several autoimmune diseases and was approved in Europe in 2008 in combination with MTX to treat rheumatoid arthritis. A European patent granted to Genentech covering this indication was subsequently revoked in opposition proceedings after an appeal to the Technical Board of Appeal (TBA) of the EPO.

The TBA considered that the patent (EP1176981) was obvious because medical practice at the relevant time was to combine virtually all new agents with MTX. It therefore would have been obvious to combine a new biological agent such as rituximab with MTX. There was also an incentive for this to happen, given the urgent need for improved treatments for rheumatoid arthritis. As a result, the patent was not inventive and was revoked.

Another example is the combination of trastuzumab (the originator product Herceptin) and a taxoid to treat malignant HER2-positive breast cancer. Genentechs EP1037926, covering this indication, was revoked during opposition proceedings in the EPO on the basis that the invention was obvious. In those proceedings, the TBA summarised the approach of the EPO in considering obviousness as follows: a course of action can be considered obvious if the skilled person would have carried it out in expectation of some improvement or advantage. Thus, obviousness is not only present when results are clearly predictable but also when there is a reasonable expectation of success In the case of the trastuzumab combination, because monotherapy with the taxoid drug paclitaxel was a well-known treatment for breast cancer and the two drugs are directed at different molecular targets, the TBA considered that it would be obvious to combine them.

The approach of the UK courts

Despite these examples, it is likely that EPO will grant many more combination patents for biologics and small molecules where the patentee is able to provide evidence of an unexpected treatment benefit. The UK courts usually do not take the same approach to obviousness as the EPO, so these patents may be vulnerable to attack. Of particular importance is the role which experts play in invalidity proceedings in the UK, where their opinion can provide valuable context about common clinical practices at the relevant priority date. This is in contrast to the more limited, document-based review performed by the EPO.

It is, of course, possible that in certain medical fields where monotherapy is standard or at least common, drug combinations may be more likely to be considered genuinely inventive. However, combination therapy is, in principle, nothing new in medicine, leaving open the prospect of invalidity challenges to granted patents to many biologic-small molecule combinations.

Originally posted here:

Patents to biological medicines in combination: is two really better than one? - Lexology